Athenex Stock

Athenex FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Athenex (ATNX) as of Aug 23, 2026 is 77.87 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 78.70 % — a change of -1.05% (lower).

FCF Conversion

77.87 %

YoY

-1.05%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Athenex is 2026 77.87 % . FCF Conversion Rate (FCF/EBITDA) of Athenex was 2025 78.70 % . It decreases by -1.05% lower compared to the previous year.

The Athenex FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
73.35 USD
Jan 1, 2016
59.35 USD
Jan 1, 2017
67.47 USD
Jan 1, 2018
96.06 USD
Jan 1, 2019
91.77 USD
Jan 1, 2020
97.49 USD
Jan 1, 2021
78.70 USD
Jan 1, 2022
77.87 USD
The Athenex FCF Conversion history
YEARFCF ConversionYoY
77.87 %-1.05%
78.70 %-19.28%
97.49 %+6.23%
91.77 %-4.47%
96.06 %+42.38%
67.47 %+13.69%
59.35 %-19.09%
73.35 %+8.34%
67.71 %—
Access this data via the Eulerpool API
Get Free API Key

Athenex Stock analysis

What does Athenex do? Athenex Inc was founded in 2003 and is headquartered in Buffalo, New York. The company specializes in the development and marketing of innovative drugs and therapies for the treatment of cancer and other serious diseases. Athenex's business model is based on collaboration with other companies and research institutions. The company works closely with academic partners to identify and develop new technologies and active ingredients. Athenex has also entered into several collaboration agreements with major pharmaceutical companies to facilitate the marketing of its products. The company has multiple divisions: Athenex Pharmaceutical Division, Athenex Oncology Division, and Athenex Pharmaceutical Technology Division. The Athenex Pharmaceutical Division focuses on the development and marketing of drugs for the treatment of cancer and other serious illnesses. The company has several promising drug candidates in its pipeline, including Oratopo, a drug for the treatment of breast cancer, and KX-2-391, a drug for the treatment of prostate cancer. The Athenex Oncology Division focuses on the development and marketing of innovative cancer treatment methods. The company has several promising therapy approaches in its pipeline, including an immunological cancer treatment based on activating the immune system to fight cancer cells. The Athenex Pharmaceutical Technology Division utilizes advanced technologies to improve the effectiveness and tolerability of drugs, including novel drug delivery systems and innovative packaging forms. Athenex also offers a wide range of products and services for the pharmaceutical industry, including drug development and manufacturing, as well as the supply of active ingredients and excipients. Overall, Athenex has a broad and interesting business model and a promising portfolio of drug candidates and therapy approaches in its pipeline. The company has also established strong partnerships with other companies and research institutions to advance its development and marketing of drugs and therapies. Athenex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athenex stock

FCF Conversion Rate (FCF/EBITDA) of Athenex is 77.87 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Athenex changed from 78.70 % to 77.87 %, representing a -1.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Athenex since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Athenex with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — Athenex

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Athenex